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Abstract 
Cerebrospinal fluid (CSF) analysis is routinely used in the diagnostic work-up of multiple 
sclerosis (MS), by detecting CSF-specific oligoclonal bands (OCB). More recently, several 
studies have reported CSF free light chains (FLC) as an alternative. We show that absolute 
CSF FLC concentrations were highly sensitive - more than OCB testing - and specific for 
clinically isolated syndrome, relapsing remitting and primary progressive MS. Measurement 
of FLC alone was sufficient. Our results suggest that CSF FLC levels measured by 
nephelometry, if validated in a larger series, are a preferred test to OCB analysis in the 
diagnostic work-up of patients suspected of having MS. 
Keywords 
Multiple sclerosis; Oligoclonal bands; Free light chains 
Highlights 
CSF free light chains in multiple sclerosis are sensitively measured by nephelometry  
CSF free light chains were highly specific for multiple sclerosis 
Analysis of CSF  free light chain concentration alone is a sufficient measurement 
Abbreviations 
FLC - free light chains; OCB - oligoclonal bands; CIS - clinically isolated syndrome; CSF -
cerebrospinal fluid; RR-MS - relapsing remitting MS; PP-MS - primary progressive MS. 
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1. Introduction 
The pathogenesis of multiple sclerosis (MS) involves inflammatory demyelination, thought to 
involve the activation of autoreactive T cells that in turn activate microglia and recruit 
macrophages, which cause demyelination and subsequent neurological damage (Disanto et al. 
, 2010; Nylander and Hafler, 2012). In addition, meningeal ectopic B cell follicles and 
plasmablasts in the CSF have been reported; these cells are also likely to contribute to the 
pathology of MS (Aloisi et al. , 2010; Meinl et al. , 2006). Despite refinements in MRI 
imaging protocols for the diagnosis of MS, the detection of intrathecal immunoglobulin, 
produced by these central nervous system resident B cells, continues to be an important  
component of the diagnostic pathway for MS (Katsavos and Anagnostouli, 2013; Tumani et 
al. , 2009). In addition to diagnostic information, particularly when MRI imaging is 
inconclusive, the presence of CSF specific OCB may provide prognostic information, for 
example in the prediction of conversion from clinically isolated syndrome (CIS), the first 
presenting neurological event, to relapsing remitting disease (RR-MS) (Villar et al. , 2012). 
 
Traditionally, the assay for the presence of CSF immunoglobulin is performed using gel 
isoelectrofocusing and immunoblotting, allowing the visualisation of oligoclonal bands which 
may or may not be mirrored in the matched serum sample (Katsavos and Anagnostouli, 2013; 
Tumani et al., 2009). There are many difficulties with this test including requirements for a 
matched serum sample, manual handling, limited sensitivity and the potential for subjective 
interpretation. In an attempt to address these issues, a number of recent studies have 
employed the detection of CSF free light chains (FLC) as a measure of intrathecal 
immunoglobulin synthesis (Arneth and Birklein, 2009; Duranti et al. , 2013; Kaplan et al. , 
2013; Presslauer et al. , 2008; Senel et al. , 2014; Villar et al., 2012). Light chains are 
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produced in excess during antibody formation and are secreted from the plasma 
cells/plasmablasts, with a serum half-life of 2-6 hours primarily through renal clearance 
(Solling, 1981). This pathway is absent for the CSF and FLC levels may therefore remain 
elevated for prolonged periods, to the point where even very small amounts of intrathecal 
FLC synthesis become detectable. The majority of studies on FLC in the CSF have shown an 
increased sensitivity and specificity for MS diagnosis as compared to traditional OCB 
detection (Arneth and Birklein, 2009; Duranti et al., 2013; Kaplan et al., 2013; Presslauer et 
al., 2008; Villar et al., 2012). However, the specific results vary according to the assay 
methodology, using  either ELISA or nephelometry (Senel et al., 2014) which may have 
different sensitivities, and with the use of an index measure of FLC (Duranti et al., 2013; 
Messaoudani et al. , 2014; Presslauer et al., 2008), for example (CSF FLC/serum FLC)/(CSF 
albumin/serum albumin). In our study we have performed analysis of  and  FLC by 
nephelometry and demonstrate that the concentration of FLC alone provides a high degree 
of sensitivity and specificity in MS.  
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2. Materials and Methods 
2.1 Study Subjects 
Ethical approval for the study was provided by the Human Biorepository Research Centre 
(HBRC), University of Birmingham. All subjects provided written informed consent to 
participate in this study. Between February 2011 and September 2013, matched serum and 
CSF samples were prospectively collected from 160 patients who underwent routine 
diagnostic lumbar puncture as elective cases on the Neurology day-case unit at the Queen 
Elizabeth Hospital, Birmingham (QEHB).  
 
The following diagnostic groups were established: CIS, RR-MS, primary progressive MS 
(PP-MS), fulfilling the criteria of dissemination in space and time for diagnosis of MS 
according to recent criteria (Polman et al. , 2011), other neurological inflammatory diseases 
(ONID) and other neurological diseases (OND). CIS patients therefore had evidence of one 
attack, with objective clinical evidence of one lesion, but no evidence of dissemination in 
time (clinically or radiologically). The majority of MS patients were not receiving any 
disease-modifying treatment at time of lumbar puncture except one PP-MS patient who was 
taking methotrexate and one RR-MS patient who had been prescribed TYSABRI
®
, but had 
not received it in the 30 days prior to lumbar puncture. Two MS patients (one CIS and one 
RR-MS) had received a course of steroid therapy in the month prior to CSF collection. The 
details of the patient cohorts are given in Table 1. 
 
2.2. Preparation of CSF and serum 
Peripheral blood was collected in serum clotting tubes (Serum Sep Vacuette; Greiner 
BioOne, Germany) and allowed to clot for 20 min at room temperature before centrifugation 
(700g, 20 min), and stored at -80°C until analysis. A mean volume of 6 ml (range 2-24 ml) of 
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CSF was obtained by non-traumatic lumbar puncture. CSF was centrifuged (400g, 8 min) and 
the supernatant collected and frozen at -80
o
C until analysis. The cell pellet was analyzed by 
flow cytometry (Cyan ADP High Performance flow cytometer; Beckman Coulter, High 
Wycombe, UK), with the addition of counting beads (Life Technologies, U.K.) to obtain a 
lymphocyte count. Only matched serum and CSF samples with adequate volume were 
included for analysis in the study. 
 
2.3. Free light chain quantification 
FLC concentrations were measured by nephelometry using the latex particle-enhanced, 
Freelite® κ and λ immunoassays (The Binding Site Group Ltd, Birmingham, U.K.) (Bradwell 
et al. , 2001) on a Dade-Behring BN ™ II Analyser, following the manufacturer’s 
instructions. CSF samples were measured without dilution. Normal serum reference intervals 
were used: κFLC 3.3 – 19.4 mg/L and λFLC 5.7 – 26.3 mg/L with an assay sensitivity of < 1 
mg/L (Katzmann et al. , 2002). Normal CSF reference intervals have not been defined. The 
limit of detection for the κFLC assay was 0.06 mg/L and 0.05 mg/L for the λFLC assay.  
 
2.4 Data analysis 
Data were analysed using GraphPad Prism 5 (GraphPad Software Inc., CA, USA). Statistical 
analysis used non parametric testing as specified. 
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3. Results 
3.1 Measurement of FLC 
The levels of CSF FLC were significantly elevated in all 3 MS groups, CIS, PP-MS, and 
RR-MS, as compared to either the OND or ONID control groups (Fig. 1A, Table 2). By 
contrast, the levels of CSF FLC, although elevated in all MS groups as compared to OND 
and ONID, failed to reach statistical significance in all cases; for the CIS and PP-MS groups 
there was a significant increase as compared to OND but not ONID. Interestingly, for the 
RR-MS group CSF FLC levels were significantly elevated as compared to both OND and 
ONID groups (Fig. 1B). There were no significant differences in the levels of CSF  or  
FLC between the MS groups, or serum  or  FLC between all groups (Fig. 1 C,D). The 
levels of CSF FLC approached those detectable in the serum (Table 2). 
Receiver operator characteristic (ROC) analysis revealed that measurement of CSF FLC 
levels produced a high degree of sensitivity and specificity (Fig. 2 A,B), which was far 
superior to that with FLC (Fig. 2 C,D), and not further enhanced by combining the values 
for CSF  and FLC (Fig. 2 E,F, Table 3), although the area under the curve was slightly 
elevated. For comparison of the measurement of  and FLC, as well as ratio measurements, 
the cut-off used was the level that resulted in a specificity of 98%. The characteristics of the 
ROC analysis were maintained for both the CIS alone (Fig. 2B,D,F), and when analysing all 
MS cohorts as a single group (Fig. 2A,C,E). A comparison of the CSF OCB and FLC data 
for the MS group showed that there was a significant elevation of CSF FLC in the CSF 
OCB positive vs. negative group (Fig. 2G). Importantly, 4/6 MS patients (2 CIS, 1 PP-MS, 1 
RR-MS) that returned a negative CSF OCB test were positive for CSF FLC when using a 
cut-off of 0.9 mg/L. A single RR-MS patient with a positive CSF OCB was very marginal at 
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this cut-off (0.95 mg/L) and one non-MS patient, that interestingly was also positive for the 
OCB test, was positive for CSF FLC. There were two patients in the MS group (1 CIS, 1 
RR-MS) that remained negative for both tests. 
To account for potential influence of a breakdown of endothelial barriers in the CNS, total 
CSF protein was also measured. The ratio of CSF FLC to total protein, for both  and  FLC, 
showed very similar patterns and levels of significance to those using the CSF FLC 
measurement alone (Fig. 3A,B). Although ROC analysis demonstrated that the sensitivity and 
specificity were very high, they did not increase above the level for FLC alone (Fig. 3C, 
Table 3). A similar analysis of CSF to serum FLC ratios also showed similar results but again 
failed to enhance sensitivity or specificity (data not shown). There was no correlation with T2 
lesion load (Fig. 4A), but there was a weak but significant correlation between CSF FLC 
and the concentration of lymphocytes in the CSF (Fig. 4B). 
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Discussion 
In this study we have demonstrated that nephelometric measurement of FLC in CSF is 
highly sensitive and specific for CIS, PP-MS and RR-MS, classifying a number of 
individuals that were negative using traditional OCB testing. These data add to the growing 
number of studies that have shown the utility of CSF FLC measurement in the diagnosis of 
MS (Duranti et al., 2013; Kaplan et al., 2013; Messaoudani et al., 2014; Presslauer et al., 
2008; Senel et al., 2014), and that this assay can be more sensitive than OCB testing. In 
addition we show that a  FLC concentration measurement alone is sufficient to provide this 
high level of sensitivity and specificity in suspected MS. If validated in a larger series, this 
method will be an easier way of studying intrathecal immunoglobulin synthesis with a 
sensitivity and specificity at least comparable to that of oligoclonal IgG bands. 
 
The samples were collected prospectively for diagnosis and we are currently awaiting follow-
up data on the CIS (n=21) group to determine the frequency and rate of conversion to 
definitive MS. Given the concordance with the OCB data it is likely that the majority will 
relapse given enough time. Reports also suggest that FLC measurements might predict 
conversion to MS (Villar et al., 2012), so it will be important to determine if the FLC 
measurement alone is sufficient to predict conversion and/or relate to the frequency of future 
relapses and/or disease progression as this could provide prognostic information and 
potentially inform treatment approaches. There were a small number of outlier samples, 
which did not show the predicted levels of FLC in the CSF, and it will be interesting to 
determine in follow-up if these ultimately were clinically misclassified or display a different 
disease phenotype.  
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The levels of CSF FLC have been shown to relate to the number of CSF cells (Senel et al., 
2014), and we were able to confirm that CSF FLC levels in a combined cohort of CIS, PP-
MS and RR-MS correlated with cellularity of the CSF. There may be a number of reasons for 
this association, which fall beyond the scope of this current study but are the subject of 
ongoing investigations. Firstly, the cellular infiltrate is known to include B cells and plasma 
cells/blasts (Meinl et al., 2006) and therefore the amount of secreted antibody and associated 
excess FLC may be proportional to the number of these cells in the CSF. The increased levels 
of CXCL13 in MS CSF (Khademi et al. , 2011), which were also shown to correlate with 
FLC levels (Senel et al., 2014) suggest that this may indeed be the case but this requires 
confirmation by direct measurement of plasma cell/blast number and FLC levels. Secondly, 
at least some of the FLC may be coming from tissue-resident plasma cells/blasts, and the 
FLC levels are therefore more likely to be related to the degree of tissue inflammation. This 
may be related to the time since the beginning of the CIS or relapse, as CSF samples are 
collected at varying time points after onset of the neurological episode.  
 
The measurement of FLC, rather than the whole antibody molecule, is currently based on 
the superior sensitivity of the FLC assay. The detection of different isotypes of Ig associated 
with  (or ) FLC might provide further diagnostic or prognostic information, but their utility 
in MS has yet to be determined. Although nephelometry is widely used within clinical 
diagnostic laboratories, an ELISA format could also be of benefit in some laboratories that do 
not have access to nephelometry equipment. However, a recent study by Senel et al., who 
used an ELISA based system, failed to show any increased sensitivity or specificity of the 
FLC assay over traditional OCB testing (Senel et al., 2014). The very high values for both 
sensitivity and specificity in our study using nephelometry, allowed detection of FLC in some 
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OCB negative samples from CIS and RR-MS patients and combined with data from other 
recent studies using the same technique (Duranti et al., 2013; Presslauer et al., 2008; Villar et 
al., 2012), suggest that this nephelometric test for FLC, even when used without an index 
measurement, provides an excellent test for the confirmation of CIS/MS. If validated in a 
larger series, the use of this more sensitive test would allow for early treatment with the 
increasingly large range of immunomodulatory treatments becoming available, and 
potentially provide prognostic information on the likelihood of early conversion to MS 
(Villar et al., 2012).  
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Figure legends 
Figure 1. Free light chains (FLC) are elevated in the cerebrospinal fluid (CSF) from 
patients with multiple sclerosis (MS), but not other neurological diseases. The levels of 
FLC and FLC were measured in matched CSF (A,B) and peripheral blood serum samples 
(C,D), taken at the time of the diagnostic lumbar puncture. CIS, clinically isolated syndrome; 
PP-MS, primary-progressive MS; RR-MS, relapsing-remitting MS; OND, other neurological 
disease; ONID, other neurological inflammatory disease. Kruskal-Wallis multiple group 
comparison with Dunn’s post test; **, p<0.01, ***, p<0.001. All other comparisons were not 
significant (p>0.05). 
 
Figure 2. Receiver operator characteristic (ROC) analysis of cerebrospinal fluid (CSF)  
free light chain (FLC) reveals a high degree of sensitivity and specificity for multiple 
sclerosis (MS). ROC curves are shown for CSF FLC (A,B), FLC (C,D), and combined  
and  FLC levels (E,F). The levels of CSF FLC (cut-off dotted line of 0.9mg/L) in MS and 
non-MS groups subdivided according to a positive oligoclonal band (OCB) (G).  CIS, 
clinically isolated syndrome.   
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Figure 3. Determining the ratio of cerebrospinal fluid (CSF) free light chain (FLC) to 
total protein does not increase sensitivity or specificity for multiple sclerosis (MS).  The 
levels of CSF  and  FLC per unit protein in the CSF were determined for each group (A,B). 
CIS, clinically isolated syndrome; PP-MS, primary-progressive MS; RR-MS, relapsing-
remitting MS; OND, other neurological disease; ONID, other neurological inflammatory 
disease. Kruskal-Wallis multiple group comparison with Dunn’s post test; *, p<0.05; **, 
p<0.01, ***, p<0.001. All other comparisons were not significant (p>0.05). Receiver operator 
characteristic curves are shown for CSF FLC/protein (C).  
 
Figure 4. Cerebrospinal fluid (CSF)  free light chain (FLC) levels correlate with CSF 
lymphocyte cell number but not T2 lesion load. Correlations between CSF FLC and T2 
lesion load (A) and CSF cells/ml (B). CIS, clinically isolated syndrome; PP-MS, primary-
progressive MS; RR-MS, relapsing-remitting MS. Spearman correlation. 
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Patient group n      Gender      Age Diagnosis 
                      M/F median (range) 
 
Clinically-isolated 21   6/15 37 (21-70)   
syndrome (CIS) 
 
Primary-progressive 11   5/6 51 (43-72) 
MS (PP-MS) 
 
Relapsing-remitting 21   3/18 40 (19-72) 
MS (RR-MS) 
 
Other neurological 90   24/66 44.5 (17-85) CSF pathways disease (4), Miscellaneous (12), Acute neurodegenerative 
disease (OND)      disease (6), Undetermined (17), Functional (2), Headache syndrome (24),  
      Degenerative (5), Idiopathic intracranial hypertension (8), Anxiety (3), 
      Neuropathy (4), Vascular (1), Pain syndrome (4) 
 
Other neurological 17   10/7 53 (24-83) APS, Behçet’s (2), Assymetric axonal neuropathy, 
inflammatory disease       Compressive myelopathy (2), Anti-MAG neuropathy, Neuroretinitis,   
(ONID)       Sjogrens syndrome, Idiopathic transverse myelitis, Aseptic meningitis, 
       Inflammatory cervical myelopathy, 
       Longitudinally Extensive Transverse Myelitis, Vasculitic sensory neuropathy, 
       Neurosarcoidosis (2), Chronic inflammatory demyelinating polyneuropathy 
 
Table 1. Patient characteristics.  
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Patient  Sample FLC (mg/L)  FLC (mg/L)  FLC/protein  
group   type  (median; range) (median; range) (median; range) 
 
CIS
a
  CSF  8.08; 0.06-26.03 0.25; 0.10-9.49 22.52; 0.24-98.25 
  Serum  12.88; 2.09-22.10 13.89; 7.73-55.54 ND
b
  
 
PP-MS  CSF  7.56; 1.61-35.56 0.80; 0.08-3.96 24.39; 3.59-93.16 
  Serum  12.34; 1.79-20.08 13.48; 2.22-17.56 ND 
 
RR-MS  CSF  8.01; 0.14-29.12 1.29; 0.05-7.99 29.84; 0.63-87.08 
  Serum  10.78; 6.42-22.23 11.35; 7.00-19.83 ND 
  
OND   CSF  0.14; 0.06-0.79 0.08; 0.05-0.36 0.47; 0.10-2.83 
  Serum  11.73; 1.59-74.52 13.20; 5.25-72.64 ND 
 
ONID   CSF  0.25; 0.06-4.47 0.17; 0.05-0.71 0.54; 0.17-13.54 
  Serum  13.77; 2.01-30.15 13.57; 5.78-45.86 ND 
 
 
 
Table 2. CSF and serum free light chain (FLC) levels. 
a
CIS, clinically isolated syndrome; 
PP-MS, primary-progressive MS; RR-MS, relapsing-remitting MS; OND, other neurological 
disease (OND); ONID, other neurological inflammatory disease. 
 b
ND; not determined.
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Comparison  Sensitivity Specificity Area under curve Cut-off used  
   (%)  (%)     (mg/L)   
CSF FLC   
All MS vs. non-MS 96.2  98.1  0.971   0.87 
CIS vs. non-MS 95.2  98.1  0.953   0.99 
 
CSF FLC 
All MS vs. non-MS 60.4  98.1  0.918   0.57 
CIS vs. non-MS 33.3  98.1  0.904   0.59 
 
CSF +FLC     
All MS vs. non-MS 96.2  98.1  0.980   1.47 
CIS vs. non-MS 95.4  98.1  0.981   1.54 
       
CSF FLC/protein        (ratio) 
All MS vs. non-MS 94.2  98.1  0.975   2.98 
CIS vs. non-MS 95.0  98.1  0.957   2.98 
 
 
Table 3. Receiver operator characteristic analysis of CSF free light chain (FLC) levels.  
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